| Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. | |
| | |
MedLine Citation:
|
PMID: 23287454 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The development of drugs that inhibit platelets has been driven by a combination of clinical insights, fundamental science, and sheer luck. The process has evolved as the days of stumbling on therapeutic gems, such as aspirin, have long passed and have been replaced by an arduous process in which a drug is designed to target a specific protein implicated in a well-characterized pathophysiological process, or so we would like to believe. The development of antiplatelet therapy illustrates the importance of understanding the mechanisms of disease and the pharmacology of the compounds we develop, coupled with careful clinical experimentation and observation and, yes, still, a fair bit of luck. |
| | |
Authors:
|
Desmond J Fitzgerald; Garret A Fitzgerald |
Related Documents
:
|
23454534 - The histone deacetylase inhibitor sodium butyrate modulates acquisition and extinction ... 23450374 - Exploiting online discussions to discover unrecognized drug side effects. 14652464 - Intravenous sodium valproate in status epilepticus. 9587044 - Pharmacological management of epilepsy. mechanism of action, pharmacokinetic drug inter... 6090354 - An improved hplc assay for s-2-(3-aminopropylamino)ethyl phosphorothioate (wr-2721) in ... 1467454 - Moxisylyte plasma kinetics in humans after intracavernous administration. |
Publication Detail:
|
Type: Historical Article; Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Circulation research Volume: 112 ISSN: 1524-4571 ISO Abbreviation: Circ. Res. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-01-04 Completed Date: 2013-02-27 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0047103 Medline TA: Circ Res Country: United States |
Other Details:
|
Languages: eng Pagination: 174-94 Citation Subset: IM |
Affiliation:
|
UCD Conway Institute and Java Clinical Research, University College Dublin, Ireland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Aspirin / therapeutic use Blood Platelets / drug effects*, enzymology Cardiovascular Diseases / blood, drug therapy*, history Cyclooxygenase Inhibitors / administration & dosage, adverse effects, history, therapeutic use* Dose-Response Relationship, Drug Drug Discovery* / history Drug Resistance Evidence-Based Medicine History, 20th Century History, 21st Century Humans Pharmacogenetics Platelet Aggregation Inhibitors / administration & dosage, adverse effects, history, therapeutic use* Purinergic P2Y Receptor Antagonists / administration & dosage, adverse effects, history, therapeutic use* Ticlopidine / analogs & derivatives, therapeutic use Translational Medical Research* / history |
| Grant Support | |
ID/Acronym/Agency:
|
HL062250/HL/NHLBI NIH HHS; U54 HL117798/HL/NHLBI NIH HHS; U54HL117798/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Cyclooxygenase Inhibitors; 0/Platelet Aggregation Inhibitors; 0/Purinergic P2Y Receptor Antagonists; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; A74586SNO7/clopidogrel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An electrophysiological investigation of non-symbolic magnitude processing: Numerical distance effec...
Next Document: Membrane-associated matrix proteolysis and heart failure.